Frank Clyburn built one of oncology’s most profitable franchises from the ground up. Keytruda, the pembrolizumab immunotherapy he shepherded at Merck, reshaped cancer treatment and generated tens of billions in revenue. Now he’s joining the board of Real Chemistry, a healthcare marketing and analytics firm betting its future on artificial intelligence.
The appointment landed Tuesday alongside a second board addition: Christopher Fikry, the physician-turned-executive who led clinical trial data provider Clario before Thermo Fisher Scientific acquired it.
For Real Chemistry, the dual hires signal ambition. The 2,400-person firm operates at the intersection of pharmaceutical commercialisation and AI-driven audience insights—a market where drug manufacturers increasingly spend to understand prescribers, patients, and payers. Clyburn and Fikry bring decades navigating those exact stakeholders.
“With the addition of Frank and Chris, Real Chemistry is even better positioned to navigate changes across the commercial lifecycle of healthcare brands and shape the future of our industry through advances in AI and technology,” said Shankar Narayanan, the company’s chief executive.
He wasn’t subtle about the value proposition.
“Frank brings deep commercialization expertise and a clear perspective for where the industry is heading, including the evolution of major therapeutic areas and the growing role of the consumer. Chris brings strong experience transforming large data- and technology-enabled life sciences businesses. Together, they will sharpen our ability to deliver for clients at scale and speed.”
Clyburn spent 13 years at Merck, rising to executive vice president and division president of human health. That role gave him oversight of the pharmaceutical giant’s entire medicine and vaccine portfolio. Earlier, he ran the primary care business line, managing diabetes and cardiovascular franchises, before taking charge of global oncology.
That’s where Keytruda happened.
The immunotherapy—approved across multiple tumour types—became one of the fastest-growing oncology drugs in history. Clyburn led the franchise from inception, positioning it as a cornerstone of modern cancer care. He later moved to International Flavors & Fragrances as chief executive and board member, steering a company spanning food ingredients, beverages, scent, and biosciences.
Currently, he holds board seats at three firms: Cencora, Revolution Medicines, and Kailera Therapeutics. All three operate in life sciences or pharmaceutical distribution.
Fikry brings a different pedigree—one rooted in data infrastructure rather than drug commercialisation. As chief executive of Clario, he ran a business that provided endpoint data solutions for clinical trials. Thermo Fisher Scientific acquired the company in what the press release lists as a 2026 transaction, though that appears to reference either a future milestone or a typographical error.
He continues leading Clario as a division within Thermo Fisher’s sprawling life sciences apparatus. Before that, Fikry served as president of laboratory services at PPD, the contract research organisation also owned by Thermo Fisher. There, he oversaw global teams delivering end-to-end solutions across drug development—from early planning through commercialisation.
The appointments arrive as Real Chemistry marks its 25th anniversary. Founded in 2000, the firm positions itself as a tier-one commercialisation partner to pharmaceutical and healthcare companies. Its model blends AI-powered audience analytics with creative marketing and strategic communications—capabilities designed to help life sciences firms reach physicians, patients, and healthcare decision-makers more precisely.
The company’s brand portfolio includes 21GRAMS, a creative agency that’s collected industry awards, and starpower, a practice focused on celebrity and influencer engagement. Real Chemistry operates offices across North America, Europe, and the Middle East, supported by partner networks in Asia Pacific, Latin America, and Africa.
What the announcements don’t address: whether the board expansion precedes a funding round, acquisition discussions, or public offering preparations. Private companies often add independent directors with marquee credentials when exploring strategic options.
The healthcare marketing sector has seen consolidation in recent years, with holding companies and private equity firms acquiring agencies that serve pharmaceutical clients. Real Chemistry’s emphasis on AI and data analytics positions it within a competitive landscape where technology differentiation increasingly matters.
For Clyburn and Fikry, the board seats add to portfolios already heavy with life sciences commitments. Both men bring networks across pharmaceutical executives—precisely the audience Real Chemistry needs to reach as it pitches commercialisation services.
Whether those connections translate into client wins remains the unanswered question. Board members typically don’t involve themselves in day-to-day sales, but their presence signals credibility to potential customers evaluating vendors.
The timing also coincides with broader pharmaceutical industry interest in AI tools that promise to sharpen marketing precision and improve return on promotional spending. Drug manufacturers face pricing pressure, patent cliffs, and regulatory scrutiny—forces that make efficient commercialisation more valuable.
Real Chemistry’s pitch hinges on using AI to analyse audiences and optimise how pharmaceutical brands communicate with stakeholders. That requires understanding both the technology and the therapeutic landscapes where drugs compete.
Clyburn’s experience launching and scaling major franchises across oncology, diabetes, and cardiovascular disease gives him perspective on how commercial teams operate inside pharmaceutical companies. Fikry’s background building data and technology businesses offers insight into the infrastructure that enables precision marketing.
Together, they represent exactly the expertise a healthcare marketing firm would want in the room when shaping strategy. What’s less certain is how quickly that expertise converts into market share gains against competitors also chasing the same pharmaceutical marketing budgets.
